Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy

Pierpaolo Falcetta a, Michele Aragona b, Annamaria Ciccarone b, Alessandra Bertolotto b, Fabrizio Campi b, Alberto Coppelli b, Angela Dardano a, Rosa Giannarelli b, Cristina Bianchi b, Stefano Del Prato a,*

a Department of Clinical & Experimental Medicine, Section of Metabolic Diseases & Diabetes, University of Pisa, Pisa, Italy
b Section of Metabolic Diseases & Diabetes, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

ABSTRACT

Aims: to evaluate the effect of home confinement related to COVID-19 lockdown on metabolic control in subjects with T2DM in Italy.

Methods: we evaluated the metabolic profile of 304 individuals with T2DM (65% males; age 69 ± 9 years; diabetes duration 16 ± 10 years) attending our Diabetes Unit early at the end of lockdown period (June 8 to July 7, 2020) and compared it with the latest one recorded before lockdown.

Results: There was no significant difference in fasting plasma glucose (8.6 ± 2.1 vs 8.8 ± 2.5 mmol/L; P = 0.353) and HbA1c (7.1 ± 0.9 vs 7.1 ± 0.9%; P = 0.600) before and after lockdown. Worsening of glycaemic control (i.e., ΔHbA1c ≥ 0.5%) occurred more frequently in older patients (32.2% in > 80 years vs 21.3% in 61–80 years vs 9.3% in < 60 years; P = 0.05) and in insulin users (28.8 vs 16.5%; P = 0.012). On multivariable analysis, age > 80 years (OR 4.62; 95%CI: 1.22–16.07) and insulin therapy (OR 1.96; 95%CI: 1.10–3.50) remained independently associated to worsening in glycaemic control.

Conclusions: Home confinement related to COVID-19 lockdown did not exert a negative effect on glycaemic control in patients with T2DM. However, age and insulin therapy can identify patients at greatest risk of deterioration of glycaemic control.

ARTICLE INFO

Keywords:
Covid-19
Lockdown
Type 2 diabetes
Metabolic control
Age
Insulin therapy

1. Introduction

Since its first recognition in Wuhan, China, in December 2019, the COVID-19 pandemic caused by the novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2) has rapidly spread across the globe. In the absence of effective treatments or vaccines, measures have been deployed to slow the spreading of the viral infection by implementing social distancing and lockdowns of large sections of the society. In Italy, a nationwide lockdown was imposed from March 9th through May 3rd, 2020. For people with diabetes the lockdown can be expected to exert a negative impact on the management of the disease due to the anxiety and depression that can be generated by the concern about the risk of infection for them and their relatives as well as because of the uncertainties about medical and pharmacologic supply and the possibility to access regularly consultation with health care providers. In spite of this view, data in people with type 1 dia-
Continuous variables are expressed as mean with standard deviation (SD) and median with interquartile range (IQR); categorical variables are expressed as percentages. Normality was checked using the Shapiro–Wilk test. Paired Student’s t-test was used to compare paired continuous variables with normal distribution, while the Wilcoxon Rank test was used for not-normally distributed paired variables. A univariate and multivariable logistic regression analysis was applied to evaluate the association of age, sex, BMI, diabetes duration, presence of micro- and macrovascular complications with glycaemic control potentially associated with a worsening of HbA1c defined as an increase ≥ 0.5%. Finally, a sensitivity analysis including only those subjects with the last visit within three months before lockdown was performed. Statistical significance was accepted at two-tailed P < 0.05. Data were analysed using SPSS version 25 (IBM SPSS Statistics).

3. Results

Out of 1250 patients referred to the Diabetes Unit in the selected period, 946 were excluded due to change in therapy at the last visit before lockdown or because of missing HbA1c data. The main clinical characteristics of the remaining 304 patients with T2DM are shown in Table 1.

The mean time between the pre- and post-lockdown visit was 6.5 ± 1.6 months (median 6.2 months [IQR, 5.6–7.3]). On average, pre-lockdown visit was carried out 3.1 ± 1.5 months (median 2.9 months [IQR, 2.0–4.0]) before lockdown. Table 2 shows the anthropometric and biochemical data of the whole cohort before and after lockdown.

Overall, minor numerical changes were apparent for almost all parameters considered, though BMI, WC, and creatinine were significantly higher while eGFR, total, LDL- and HDL-cholesterol were lower after lockdown compared to baseline. No statistically different changes were found as far

### Table 1 – Clinical characteristics of the entire cohort at baseline.

| Variable            | N   | N%    |
|---------------------|-----|-------|
| Age, years          | 304 | 69.1 ± 9.2 |
| Sex, male           | 304 | 198 (65.1) |
| Smoking habit       | 214 |       |
| Never               | 99  | (32.6) |
| Current             | 31  | (10.2) |
| Former              | 84  | (27.5) |
| Unknown             | 90  | (29.6) |
| Hypertension        | 304 | 229 (75.3) |
| Dyslipidemia        | 304 | 205 (67.4) |
| CKD                 | 304 | 134 (44.1) |
| Microalbuminuria    | 304 | 81 (26.6) |
| Macroalbuminuria    | 304 | 10 (3.3)  |
| DR                  | 304 | 61 (20.1)  |
| DN                  | 304 | 64 (21.1)  |
| CVD                 | 304 | 52 (17.1)  |
| Stroke              | 304 | 10 (3.3)   |
| HF                  | 304 | 5 (1.6)    |
| PAD                 | 304 | 37 (12.2)  |
| AHAs                | 304 |         |
| Lifestyle management| 4   | (1.3) |
| Insulin             | 104 | (34.2) |
| MDI                 | 57  | (18.7) |
| Basal               | 47  | (15.5) |
| Metformin           | 261 | (85.9) |
| Sulphonylurea       | 44  | (14.5) |
| DPP4i               | 103 | (33.9) |
| GLP1-RA             | 70  | (23) |
| SGLT2i              | 47  | (15.5) |
| Pioglitazone        | 20  | (6.6) |
| Acarbose            | 8   | (2.6) |

Abbreviations: AHA, anti-hyperglycaemic agents; CKD, chronic kidney disease; CVD, established cardiovascular disease; DN, diabetic neuropathy; DR, diabetic retinopathy; GLP1-RAs, GLP1 receptor agonists; HF, heart failure; MDI, multiple daily injections insulin therapy; PAD, peripheral artery disease.

Data are expressed as mean ± SD or frequency (%).
In the present study, we report data on the impact of the COVID-19 pandemic in Italy on metabolic control of individuals with T2DM, showing that minor, though statistically significant changes were detected for some parameters but not for HbA1c, despite a slight weight gain. The robustness of our data is also confirmed by the sensitivity analysis including only patients with last follow-up visit up to 3 months (Suppl. Table 1). Upon stratification by age, a worsening in HbA1c (defined as an increase ≥ 0.5% compared to baseline value) was more common in older patients (<60 years: 9.3%; 61–79 years: 21.3%; ≥80 years: 32.2%; P < 0.05) while there were no differences across BMI categories. Similarly, no significant differences were observed between males and females (23.6 vs 19.2%; P = 0.368). Finally, HbA1c worsening occurred more commonly among those on insulin therapy as compared to those not using insulin (28.8 vs 16.5%, p = 0.012). The effect of age and insulin therapy was fully apparent in a multivariable analysis showing that minor, though statistically significant changes were detected for some parameters but not for HbA1c, despite a slight weight gain. The robustness of our data is also confirmed by the sensitivity analysis including only patients with a strict follow-up (last visit ≤ 3 months before lockdown), thus minimizing the time-dependency of the results here reported. Our results are at variance with those reported by Khare et al. in a study involving 143 patients with T2DM in whom glycaemic control, as determined on self-monitoring, worsened during the first 3 weeks of lockdown mainly because of higher post-prandial glucose levels [6]. The authors interpreted those results as the effect of changes in diet and less physical activity occurred during the lockdown.

4. Discussion

In the present study, we report data on the impact of the recent lockdown period related to the COVID-19 pandemic in Italy on metabolic control of individuals with T2DM, showing that minor, though statistically significant changes were detected for some parameters but not for HbA1c, despite a slight weight gain. The robustness of our data is also confirmed by the sensitivity analysis including only patients with a strict follow-up (last visit ≤ 3 months before lockdown), thus minimizing the time-dependency of the results here reported. Our results are at variance with those reported by Khare et al. in a study involving 143 patients with T2DM in whom glycaemic control, as determined on self-monitoring, worsened during the first 3 weeks of lockdown mainly because of higher post-prandial glucose levels [6]. The authors interpreted those results as the effect of changes in diet and less physical activity occurred during the lockdown.

On the contrary, Anjana et al. in a survey including 205 patients with T2DM found a significant improvement in HbA1c after lockdown (7.7 ± 1.7 vs 8.2 ± 1.9%, P < 0.001) [7]. More recently, in a series of 114 individuals with T2DM, Biancalana et al. reported no significant change in glucose control, although a 0.3% increase in HbA1c was found in 26% of them [4]. In summary, a certain degree of heterogeneity has been found as far as changes in glycaemic control are concerned in people with T2DM throughout the lockdown imposed to prevent the spreading of Sars-Cov-2 pandemic.

Several reasons may contribute to such heterogeneous results, including differences in ethnicity, baseline glycaemic control and access to diabetes consultation during lockdown. Baseline HbA1c value in the study by Anjana et al. was higher compared to that of our population (8.2 vs 7.1%). Furthermore, our patients may not reflect a more general diabetic population as all of them regularly attended a tertiary care Diabetes Unit that continued providing teleconsultation during the lockdown period.

Although overall no changes were detected in glycaemic control, a closer look revealed that glucose deterioration could occur in some subgroups. Thus, the percentage of the patients who had, over the lockdown, an increase of HbA1c > 0.5% was greater among the elderly and those on insulin therapy. These two parameters, age > 80 years and insulin therapy, were independently associated with significant glycaemic worsening in a multivariable analysis and, as such, they could help identifying subjects for whom it may be necessary to ensure sufficient contact and surveillance during challenging time as it was the case in the lockdown and as it has been suggested in a recent survey by Bonora et al. [8]. These authors compared accesses to the diabetes centre before and during lockdown to suggest that are the elderly patients with T2DM, i.e. those with more severe burden of complications and often requiring more complex treatment, who are likely to encounter more difficulties in stay in touch with their diabetes clinics. For these people it...
may be more difficult to get acquainted to telematic visit and monitoring systems due to poorer familiarity with modern technologies. Insulin use also was an independent predictor associated with 2-fold higher odds of glycaemic worsening compared with use of other glucose lowering agents. This may well reflect the increased complexity of the management of this therapeutic approach, particularly for those with T2DM, since evidence currently available for patients with T1DM on continuous glucose monitoring show that glycaemic control did not worsen or even improved during lockdown [1,9–12]. The latter, however, are younger, on continuous or flash glucose monitoring and more intensively instructed how to handle multiple dose insulin therapy or even continuous subcutaneous glucose infusion.

Although ours as well as other results so far available may suggest a limited impact of the lockdown on metabolic control of people with T2DM, the duration of the lockdown may have been too short to fully appreciate what could be the impact of a relaxation of diabetes management that may occur under such circumstance. In line with this caution is the modest yet statistically significant increase in body weight and waist circumference that may well reflect the initiation of a trajectory that may lead to more substantial weight gain and, ultimately, deterioration of glycaemic control. Recently published surveys showed that roughly 22% of people reported gaining weight during self-quarantine along with reduced physical activity and worse eating behaviours during the COVID-19 lockdown [13,14]. Unfortunately, due to the retrospective design of the study, data about the change in daily diet and physical activity during lockdown were not available. Nevertheless, since our patients displayed an overall stable glycaemic control, we may assume that the effect of lifestyle modifications during lockdown was negligible.

Some limitation of our study needs to be acknowledged. This includes the relatively small number of participants, although ours is the largest cohort of T2DM so far reported. Also, as already pointed out, we have recruited patients regularly attending a specialized diabetic clinic thus limiting the generalizability of our results to a broader diabetic population. Finally, the duration of the lockdown may not be sufficiently long to allow a more careful assessment of the potential impact of longer lockdown and its psychological and logistic implications.

In conclusion, the home confinement related to the COVID-19 lockdown, at least with the duration our patients have been exposed to, doesn’t seem to have exerted a negative effect on glycaemic control of patients with T2DM, despite slight weight gain. Nonetheless, some clinical features, in particular advanced age and insulin therapy, seem to be identify subgroups of patients with greater risk of glucose control deterioration. These characteristics may help in addressing patients requiring more attention - if not special protection - by developing special programmes at the time of challenging societal situations.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Acknowledgments

We would like to express our gratitude to all the patients attending the Diabetes Unit of Azienda Ospedaliero Universitaria Pisana.

### Table 3 – Logistic regression analysis for predictors of worsened HbA1c (ΔHbA1c ≥ 0.5 mmol/mol) during lockdown.

|                          | Univariate |                      |                      |                      |                      |                      |                      |                      |
|--------------------------|------------|-----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                          | OR         | 95% CI                | P                    | OR                   | 95% CI               | P                    | OR                   | 95% CI               | P                    |
| **Male sex**             |            |                       |                      |                      |                      |                      |                      |                      |                      |
| Age class                |            |                       |                      |                      |                      |                      |                      |                      |                      |
| < 60                     | 0.77       | 0.43–1.36             | 0.369                | Ref                  | Ref                  | Ref                  | Ref                  | Ref                  |
| 61–80                    | 2.64       | 0.90–7.74             | 0.077                | 2.36                 | 0.79–6.99            | 0.121                | 4.62                 | 1.22–16.07           | 0.024                |
| >80                      | 4.64       | 1.30–16.6             | **0.018**            |                      |                      |                      |                      |                      |                      |
| **BMI class**            |            |                       |                      |                      |                      |                      |                      |                      |
| Normal w                 |            |                       |                      |                      |                      |                      |                      |                      |
| Over w                   | 0.72       | 0.34–1.54             | 0.396                |                      |                      |                      |                      |                      |
| Obese                    | 1.10       | 0.53–2.28             | 0.796                |                      |                      |                      |                      |                      |
| **Microvascular Complications** |         |                       |                      |                      |                      |                      |                      |                      |
| No                       |            |                       |                      |                      |                      |                      |                      |                      |
| 1                        | 1.16       | 0.61–2.22             | 0.656                |                      |                      |                      |                      |                      |
| 2                        | 1.93       | 0.90–4.12             | 0.089                |                      |                      |                      |                      |                      |
| 3                        | 1.26       | 0.32–4.91             | 0.735                |                      |                      |                      |                      |                      |
| Macorvascular Complications, Yes |          |                       |                      |                      |                      |                      |                      |                      |
| Insulin therapy, Yes     | 1.36       | 0.70–2.26             | 0.363                |                      |                      |                      |                      |                      |
| DD, 1 year               | 2.05       | 1.17–3.61             | **0.013**            | 1.96                 | 1.10–3.50            | **0.022**            |                      |                      |
|                          | 1.00       | 0.97–1.03             | 0.903                |                      |                      |                      |                      |                      |

Abbreviations: BMI, body mass index; DD, diabetes duration.

Values in bold are statistically significant.
Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.2021.108750.

References

[1] Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP. Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. Diabetes Ther 2020;11:1–11.

[2] Verma A, Rajput R, Verma S, Balania VKB, Jangra B. Impact of lockdown in COVID-19 on glycemic control in patients with type 1 Diabetes Mellitus. Diabetes Metab Syndr 2020;14:1213–6.

[3] Fernández E, Cortazar A, Bellido V. Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diabetes Res Clin Pract 2020;166 108348.

[4] Biancalana E, Parolini F, Mengozzi A, Solini A. Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study. Acta Diabetol 2020. https://doi.org/10.1007/s00592-020-01637-y.

[5] Mosca A, Goodall I, Hoshino T, et al. Global standardization of glycated hemoglobin measurement: The position of the IFCC Working Group. Clin Chem Lab Med 2007;45:1077–80.

[6] Khare J, Jindal S. Observational study on Effect of Lock Down due to COVID 19 on glycemic control in patients with Diabetes: Experience from Central India. Diabetes Metab Syndr 2020;14:1571–4.

[7] Anjana RM, Pradeepa R, Deepa M, et al. Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown. Diabetes Technol Ther 2020;22:527–34.

[8] Bonora BM, Morieri ML, Avogaro A, Fadini GP. The Toll of Lockdown Against COVID-19 on Diabetes Outpatient Care: Analysis From an Outbreak Area in Northeast Italy. Diabetes Care. 2021;44:e18–21.

[9] Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic Control in Type 1 Diabetes Mellitus During COVID-19 Quarantine and the Role of In-Home Physical Activity. Diabetes Technol Ther 2020;22:462–7.

[10] Christoforidis A, Kavouri E, Nemtsa A, Pappa K, Dimitriadou M. Coronavirus lockdown effect on type 1 diabetes management on children wearing insulin pump equipped with continuous glucose monitoring system. Diabetes Res Clin Pract. 2020;166 108307.

[11] Maddaloni E, Coraggio L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R. Effects of covid-19 lockdown on glucose control: Continuous glucose monitoring data from people with diabetes on intensive insulin therapy. Diabetes Care 2020;43: e86–7.

[12] Aragona M, Rodia C, Bertolotto A, et al. Type 1 diabetes and COVID-19: The “lockdown effect”. Diabetes Res Clin Pract 2020;170 108468.

[13] Zachary Z, Brianna F, Brianna L, et al. Self-quarantine and weight gain related risk factors during the COVID-19 pandemic. Obes Res Clin Pract 2020;14(3):210–6.

[14] Ammar A, Chtourou H, Boukhris O, et al. COVID-19 Home Confinement Negatively Impacts Social Participation and Life Satisfaction: A Worldwide Multicenter Study. Int J Environ Res Public Health 2020;17:6237. https://doi.org/10.3390/ijerph17176237.